Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | NDUFS8 | O00217 | 5/20 | 0.43 |
| ▸ | COXFA4 | O00483 | 5/20 | 0.43 |
| ▸ | NDUFAB1 | O14561 | 5/20 | 0.43 |
| ▸ | NDUFA1 | O15239 | 5/20 | 0.43 |
| ▸ | NDUFS4 | O43181 | 5/20 | 0.43 |
| ▸ | NDUFB5 | O43674 | 5/20 | 0.43 |
| ▸ | NDUFB3 | O43676 | 5/20 | 0.43 |
| ▸ | NDUFC1 | O43677 | 5/20 | 0.43 |
| ▸ | NDUFA2 | O43678 | 5/20 | 0.43 |
| ▸ | NDUFS5 | O43920 | 5/20 | 0.43 |
| ▸ | NDUFS7 | O75251 | 5/20 | 0.43 |
| ▸ | NDUFS2 | O75306 | 5/20 | 0.43 |
| ▸ | NDUFS6 | O75380 | 5/20 | 0.43 |
| ▸ | NDUFB1 | O75438 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13714665 | 0.93 | CYP3A4 (0.49) | CYP3A4CA12CA1CA7CA9 | |
| SCHEMBL13714733 | 0.93 | CYP3A4 (0.49) | CYP3A4CA12CA1CA7CA9 | |
| SCHEMBL13714667 | 0.93 | CYP3A4 (0.49) | CYP3A4CA12CA1CA7CA9 | |
| SCHEMBL13962606 | 0.91 | CYP3A4 (0.47) | CYP3A4CA12CA1CA7CA9 | |
| SCHEMBL14511465 | 0.88 | NDUFS8 (0.41) | CYP3A4CA12CA1CA7CA9 | |
| SCHEMBL13714668 | 0.85 | CYP3A4 (0.59) | CYP3A4CA12CA1CA7CA9 | |
| SCHEMBL13714673 | 0.85 | CYP3A4 (0.59) | CYP3A4CA12CA1CA7CA9 | |
| SCHEMBL13714872 | 0.85 | CYP3A4 (0.59) | CYP3A4CA12CA1CA7CA9 | |
| SCHEMBL14495421 | 0.85 | CYP3A4 (0.42) | CYP3A4CA12CA1CA7CA9 | |
| SCHEMBL13038655 | 0.84 | CYP3A4 (0.61) | CYP3A4CA12CA1CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576124-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080039520-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039520-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | ABCG2, FABP2, HDLBP | CYP3A4 19/4885CA12 4245/4885CA1 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.